Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.: We are very pleased about it. Our application was received a very good grade in the expert assessment and was placed high on the ranking. This project in the area of metabolic diseases is currently very important to us. First we are facing toxicological tests, and after they have been completed, we will apply for the first administration of the drug in humans. We want to commence clinical development in 2018.
Jerzy Pieczykolan, PhD, Head of the Preclinical Research Department in Celon Pharma S.A: esults of the TTG in vivo test carried out on animals confirm our compound’s high activity and high effectiveness. GPR40 agonists can potentially constitute a good and safer alternative for the group of patients resistant to treatment with e.g. metformin. Additionally, these compounds do not increase the risk of hypoglycaemia
The Company’s application was submitted under the Smart Growth Operational Programme 2014-2020 Programme, measure 1.1/submeasure 1.1.1. regarding the following project: “Preclinical and clinical development of an innovative antagonist of GPR40 receptor in type 2 diabetes treatment”.
Its total cost is estimated at PLN 39.4 and the recommended value of co-funding in PLN 24.8. The project will be implemented by 2022.